心不全におけるフェロプトーシス:分子メカニズムから治療的意義まで
Konstantinos I Karampinos1, Dimitrios Farmakis1, Rijan Gurung2,3
1Department of Cardiology, Athens University Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Greece.
Cardiovascular research
|January 30, 2026
まとめ
鉄と脂質損傷によって引き起こされる細胞死の一形態であるフェロプトーシスは、心不全の進行とますます関連付けられている。フェロプトーシスを標的とすることは、心機能を回復させることで心不全の治療として有望視されている。
科学分野:
- 心血管研究
- 細胞死メカニズム
- 生物医学
背景:
- フェロプトーシスは、鉄依存性の脂質過酸化によって引き起こされる制御細胞死の一形態であり、心不全の病態形成に寄与する可能性がある。
研究 の 目的:
- 心不全におけるフェロプトーシスの役割を包括的にレビューし、その分子メカニズムと治療への影響を分析する。
主な方法:
- 心不全におけるフェロプトーシスに関する既存の文献を批判的にレビューおよび合成する。
主要な成果:
- 鉄、脂質過酸化、および制御死の文脈におけるフェロプトーシスは、心不全の病態生理において重要な役割を果たしている。
結論:
- フェロプトーシスは心不全の重要な病態生理学的メカニズムであり、治療標的となる可能性がある。
関連する概念動画
Heart Failure II: Pathophysiology
920
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction
882
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
Heart Failure VI: Adjunct Therapies
336
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
Heart Failure Drugs: Diuretics
966
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
Heart Failure V: Medical Management
312
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312


